Concurrent chemoradiotherapy (CRT) based on cisplatin is recognized as the current standard treatment for locally advanced cervical cancer. The treatment of cervical cancer has reached a plateau in the last 20 years. Previous studies have proven that the epidermal growth factor receptor is correlated with chemo- and radioresistance and treatment failure. Hence, the purpose of this study was to investigate the efficacy and safety of icotinib combined with CRT in the treatment of locally advanced cervical cancer. Eligibility criteria included patients treated in the radiotherapy department of Taizhou Central Hospital of Zhejiang Province for stage IIB to IIIB cervical cancers who had not received anti-tumor treatment before and a performance status of 0 to 2. Patients were given icotinib 125 mg three times a day for 6 weeks, which was one week before the start of radiotherapy (500 centigrays in 28 fractions) and chemotherapy (40 mg/m2 administered weekly for 3-5 cycles). There were 29 patients who completed the I + CRT treatment, and it was tolerated well. The median follow-up time was 50 months and 27 patients (93.10%) achieved complete responses. The 5-year cumulative overall survival rate and disease-free survival rate were 60.9% and 58.4%, respectively. The treatment with I + CRT is safe and effective for locally advanced cervical cancer. As far as we know, this is the first study to report the 5-year survival rate of locally advanced cervical cancer with targeted therapy combined with chemoradiotherapy.

中文翻译：

---

icotinib联合同期放化疗治疗局部晚期宫颈癌的结果。

基于顺铂的同时放化疗（CRT）被认为是当前局部晚期宫颈癌的标准治疗方法。在过去的20年中，子宫颈癌的治疗已达到平稳阶段。先前的研究已经证明，表皮生长因子受体与化学和放射抗性以及治疗失败有关。因此，本研究的目的是研究icotinib联合CRT治疗局部晚期宫颈癌的疗效和安全性。入选标准包括在浙江省泰州中心医院放疗科接受过IIB至IIIB期宫颈癌治疗且以前未接受抗肿瘤治疗且病情状态为0至2的患者。患者接受伊替替尼125 mg三次，每次3 mg一天持续6周，这是放疗开始前一周（28馏分500厘ray）和化学疗法（每周3-5次，每周40 mg / m2）开始的一周。有29例患者完成了I + CRT治疗，并且耐受性良好。中位随访时间为50个月，其中27例患者（93.10％）获得了完全缓解。5年累计总生存率和无病生存率分别为60.9％和58.4％。I + CRT治疗对于局部晚期宫颈癌是安全有效的。据我们所知，这是第一个报告靶向治疗与放化疗相结合的局部晚期宫颈癌的5年生存率的研究。有29例患者完成了I + CRT治疗，并且耐受性良好。中位随访时间为50个月，其中27例患者（93.10％）获得了完全缓解。5年累计总生存率和无病生存率分别为60.9％和58.4％。I + CRT治疗对于局部晚期宫颈癌是安全有效的。据我们所知，这是第一个报告靶向治疗与放化疗相结合的局部晚期宫颈癌的5年生存率的研究。有29例患者完成了I + CRT治疗，并且耐受性良好。中位随访时间为50个月，其中27例患者（93.10％）获得了完全缓解。5年累计总生存率和无病生存率分别为60.9％和58.4％。I + CRT治疗对于局部晚期宫颈癌是安全有效的。据我们所知，这是第一个报告靶向治疗与放化疗相结合的局部晚期宫颈癌的5年生存率的研究。I + CRT治疗对于局部晚期宫颈癌是安全有效的。据我们所知，这是第一个报告靶向治疗与放化疗相结合的局部晚期宫颈癌的5年生存率的研究。I + CRT治疗对于局部晚期宫颈癌是安全有效的。据我们所知，这是第一个报告靶向治疗与放化疗相结合的局部晚期宫颈癌的5年生存率的研究。